An interventional study of Audiometric Test and Audiometric Test in Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck and Head and Neck Carcinoma of Unknown Primary, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Emory University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 235 studies in Oropharyngeal Neoplasms with a site in United States — 63 open to participants now, 98 under way, 11 of them phase 3. Oropharyngeal Neoplasms · United States.
Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, this one is the 48th largest by planned enrollment of the 189 interventional ones that give a count, is one of 14 that started in 2025, is one of 48 with no phase, reaches primary completion later than 71 of the 97 other live ones, and was the 213th registered.
370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.
Browse Oropharyngeal Neoplasms studies →63 of the 235 studies in Oropharyngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
Metaclipse Therapeutics Corporation · Sites in United States
Ages 18+
Corbus Pharmaceuticals Inc. · Sites in United States, Austria, Belgium and 11 more countries
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
235 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 108 · Phase 3 21 · Phase 4 3
First in 1995; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 118 is above the median of 52 across 265 interventional studies indexed under Oropharyngeal Neoplasms.
Median enrollment 42 across the 189 interventional studies, 205 across the 36 observational. Of the 120 that completed or were terminated, 53 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 235 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
Emory University has 6 studies filed under Oropharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Oropharyngeal Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01266044Phase 3M.D. Anderson Cancer CenterControlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia | 2026-12-31 |
| NCT02215265Phase 3Lisette NixonPost-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) | 2027-10 |
| NCT04609280University of Maryland, BaltimoreSelective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) | 2026-12 |
| NCT05312710Aveta Biomics, Inc.Safety and Efficacy of APG-157 in Head and Neck Cancer | 2026-12 |
| NCT06319963Theravectys S.A.A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation. Cisplatin, a chemotherapy often used to treat head and neck cancers, and radiation given near the ear can cause hearing loss in some patients. Hearing loss can have a major negative impact on quality of life, contributing to social isolation and frustration. Identifying hearing changes may allow treatment changes to prevent further loss. Audiometry measures hearing loss using a graphic record of the softest sounds that a person can hear at various frequencies. It is recommended patients have a hearing test before, during and after treatment to monitor for any hearing loss. This is usually done in the office and performed on the same day as other visits whenever possible, however, patients who live far away or have stage IV cancer, may have more difficulty coming back for hearing tests. Offering close to home and remote audiometry may improve monitoring for hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation.
PRIMARY OBJECTIVE:
I. To determine whether a targeted intervention of remote audiometry offered to patients with advanced disease or living > 120 miles away increases overall participation in ototoxicity monitoring.
SECONDARY OBJECTIVE:
I. To estimate the incidence and severity of cisplatin-induced hearing loss in head and neck squamous cell carcinoma (HNSCC).
TERTIARY/EXPLORATORY OBJECTIVE:
I. To identify potential barriers to ototoxicity monitoring participation, from the patient perspective.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients undergo audiometry at Winship Emory Midtown (WEM) at baseline and at 3 and 12 months after chemotherapy and/or radiation treatment.
GROUP II: Patients who do not live > 120 miles away or do not have stage IV disease are assigned to Arm I. Patients who do live > 120 miles away or who have stage IV disease are assigned to Arm II.
ARM I (USUAL): Patients undergo audiometry at WEM at baseline and at 3 and 12 months after chemotherapy and/or radiation treatment as in Group I.
ARM II (INTERVENTION): Patients undergo audiometry at WEM at baseline and are offered closer to home audiometry or self-administered remote audiometry at 3 and 12 months after chemotherapy and/or radiation treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo audiometry at WEM at baseline and at 3 and 12 months after chemotherapy and/or radiation treatment.
Procedure: Audiometric Test · Other: Interview
Patients undergo audiometry at WEM at baseline and at 3 and 12 months after chemotherapy and/or radiation treatment as in Group I.
Procedure: Audiometric Test · Other: Interview
Patients undergo audiometry at WEM at baseline and are offered closer to home audiometry or self-administered remote audiometry at 3 and 12 months after chemotherapy and/or radiation treatment.
Procedure: Audiometric Test · Other: Interview
Undergo audiometry
Also known as: Audiometric Testing, Audiometry, Hearing Test
Undergo close to home audiometry
Also known as: Audiometric Testing, Audiometry, Hearing Test
Undergo self-administered remote audiometry
Also known as: Audiometric Testing, Audiometry, Hearing Test
Ancillary studies
Proportion of patients who complete at least one post-treatment audiogram
The incidence of follow-up audiometry relative to the targeted intervention will be assessed using a Z test for the equality of two proportions. An ordinal logistic regression analysis with mixed effects and calculations of odds ratios and 95% confidence intervals will be applied to identify associations between follow-up audiometry and intervention after adjustment for covariates including age, sex, race/ethnicity, pre-existing hearing loss, comorbidities, smoking, cisplatin dose (individual and cumulative) and cochlear radiation dose will be performed to assess whether the targeted intervention for at-risk patients is an independent predictor of increased overall participation.
Time frame: Up to 12 months post-treatment
Incidence and severity of hearing loss
Assessed using Common Terminology Criteria for Adverse Events criteria and American Speech Language and Hearing Association criteria.
Time frame: Up to 30 days following cessation of study participation
To identify potential barriers to ototoxicity monitoring participation
Qualitative data from patient interviews focused on barriers to ototoxicity monitoring.
Time frame: Up to 18 months post-treatment
Started Aug 2025 (actual). Primary completion is estimated for Jan 2029, 40 months after the start.
Of 52 non-industry interventional studies with no phase under Oropharyngeal Neoplasms, half reached primary completion within 78 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 116. This study's planned 40 months is below that.
Counting every sponsor, half of 54 studies reached it within 78 months; a quarter within 27 and three quarters within 153.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.